Cardiology

An obesity specialist discusses the importance of using a weight-first approach when educating patients about obesity's role in the development and worsening of hypertension.

The novel oral anticoagulant is one in a class of agents for prevention of AF-related stroke that shows promise to reduce bleeding risk.

"Primary care physicians... really are like the quarterbacks" for initiating multidisciplinary care for CKM syndrome, says Dr Chiadi Ndumele.

Absolute risk assessment for CVD remains the corner-stone of clinical primary prevention efforts. The new AHA prediction models expand that foundation.

Your daily dose of the clinical news you may have missed.

Patients with obesity and hypertension need to be aggressively treated in order to decrease their risk of cardiovascular complications, says Dr Jonathan Parker, President of the Alabama Obesity Society.

Managing cardiovascular-kidney-metabolic syndrome on a population-wide basis requires that social determinants of health be treated like any other risk factor, according to Ndumele.

Dr Chiadi Ndumele explains the need for the more comprehensive and also nuanced qualitative approach to estimating long-term CVD risk.

AHA 2023: Reducing daily sodium intake by about 4000 mg significantly lowered SBP in approximately 73% of adults in 1 week when compared to a higher sodium diet.

Chiadi Ndumele, MD, PhD, MHS, of Johns Hopkins University, details features of the new 4-stage construct that guides CKM diagnosis and promotes early disease intervention.

Polycystic ovary syndrome and dysmenorrhea were both identified as reproductive disorders that could help stratify CVD risk in women.

AHA 2023: An intensive 3-year treatment targeting SPB <120 mm Hg resulted in 39% lower CV mortality than standard treatment in patients with HTN at high risk of CVD.

Ndumele chairs the American Heart Association committee that characterized the syndrome and wrote the statement of evidence for its assessment and management.

Which hypertension treatment options should be used as first-line therapy in patients with obesity? A clinician's answer and explanation, here.

AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.

President of the Alabama Obesity Society, Dr Jonathan Parker, discusses obesity as a risk factor for hypertension.

Your daily dose of the clinical news you may have missed.

Only about 30% of more than 3000 adults surveyed in new poll reported talking to their clinician about the adverse effects OTC pain medications can have on blood pressure.

Uptitration of renin-angiotensin-aldosterone system inhibitors was less successful in women with acute heart failure, and particularly those with heart failure with reduced ejection fraction.

Your daily dose of the clinical news you may have missed.

President of the Alabama Obesity Society, Dr Jonathan Parker, provides an in-depth overview of the association between obesity and hypertension.

A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.

A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.

Semaglutide treatment reduced weight and was associated with greater, more consistent improvements in HFpEF than other recently studied drug classes.

Your daily dose of the clinical news you may have missed.